search

brunoamaral / gregory-ai

Artificial Intelligence and Machine Learning to help find scientific research and filter relevant content
https://gregory-ai.com/
Other
45 stars 6 forks source link

Clinical trials should include country or countries #352

Closed brunoamaral closed 11 months ago

brunoamaral commented 1 year ago

To help patients find clinical trials near them.

brunoamaral commented 12 months ago

info we get from clinicaltrials.gov:

<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>ClinicalTrials.gov: Multiple Sclerosis | First posted in the last 14 days</title>
        <link>https://clinicaltrials.gov/api/rss?cond=Multiple+Sclerosis</link>
        <description>Studies found on ClinicalTrials.gov by a search of: Multiple Sclerosis | First posted in the last 14 days</description>
        <language>en-us</language>
        <pubDate>Tue, 24 Oct 2023 07:34:34 EDT</pubDate>
        <ttl>1440</ttl>
        <item>
    <title>Effect of Cooling on Balance Performance in Multiple Sclerosis</title>
    <link>https://clinicaltrials.gov/study/NCT06094855?cond=Multiple+Sclerosis</link>
    <description>&lt;b&gt;Conditions&lt;/b&gt;: Multiple Sclerosis
&lt;br/&gt;&lt;b&gt;Interventions&lt;/b&gt;: Other: 20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest
&lt;br/&gt;&lt;b&gt;Sponsors&lt;/b&gt;: Hunter College of City University of New York
&lt;br/&gt;&lt;b&gt;Recruiting&lt;/b&gt;</description>
    <guid isPermaLink="false">NCT06094855</guid>
    <pubDate>Mon, 23 Oct 2023 00:00:00 EDT</pubDate>
</item>

info we get from clinicaltrialsregister.eu:

<?xml version="1.0" encoding="UTF-8" standalone="no"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0"><channel><title>EU Clinical Trials Register RSS Feed</title><link>https://www.clinicaltrialsregister.eu/ctr-search/search?query=multiple+AND+sclerosis</link><description>This provides a regular feed of new or updated clinical trial information published on the EU Clinical Trial Register and matching the search subscribed to.</description>
<item>
<title>A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial</title>
<link>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003874-30</link>
  <description>&lt;p&gt;EudraCT Number: 2020-003874-30&lt;br/&gt;Sponsor Protocol Number: MS700568_0158&lt;br/&gt;Sponsor Name: Merck Healthcare KGaA&lt;br/&gt;Start Date: 2021-02-03&lt;br/&gt;Medical condition: Highly-active relapsing multiple sclerosis&lt;br/&gt;Disease: &lt;br/&gt;Version: 20.0&lt;br/&gt;SOC Term: 10029205 - Nervous system disorders&lt;br/&gt;Classification Code: 10029205&lt;br/&gt;Term: Nervous system disorders&lt;br/&gt;Level: SOC&lt;br/&gt;Version: 20.1&lt;br/&gt;SOC Term: 10029205 - Nervous system disorders&lt;br/&gt;Classification Code: 10028245&lt;br/&gt;Term: Multiple sclerosis&lt;br/&gt;Level: PT&lt;br/&gt;Version: 21.0&lt;br/&gt;SOC Term: 10029205 - Nervous system disorders&lt;br/&gt;Classification Code: 10080700&lt;br/&gt;Term: Relapsing multiple sclerosis&lt;br/&gt;Level: PT&lt;br/&gt;&lt;br/&gt;Population Age: Adults, Elderly&lt;br/&gt;Gender: Male, Female&lt;br/&gt;Trial Protocol: &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/CZ"&gt;CZ&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/HU"&gt;HU&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/SK"&gt;SK&lt;/a&gt; (Ongoing), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/DK"&gt;DK&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/AT"&gt;AT&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/IT"&gt;IT&lt;/a&gt; (Ongoing)&lt;/p&gt;</description><guid>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003874-30</guid>
</item>
<item><title>A 2-year extension study to evaluate long-term effectiveness of Mavenclad® in participants who have completed Trial MS700568_0022 (MAGNIFY MS)</title><link>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003995-42</link><description>&lt;p&gt;EudraCT Number: 2020-003995-42&lt;br/&gt;Sponsor Protocol Number: MS700568_0157&lt;br/&gt;Sponsor Name: Merck Healthcare KGaA&lt;br/&gt;Start Date: 2020-12-18&lt;br/&gt;Medical condition: Highly-active relapsing multiple sclerosis&lt;br/&gt;Disease: &lt;br/&gt;Version: 20.0&lt;br/&gt;SOC Term: 10029205 - Nervous system disorders&lt;br/&gt;Classification Code: 10029205&lt;br/&gt;Term: Nervous system disorders&lt;br/&gt;Level: SOC&lt;br/&gt;Version: 20.1&lt;br/&gt;SOC Term: 10029205 - Nervous system disorders&lt;br/&gt;Classification Code: 10028245&lt;br/&gt;Term: Multiple sclerosis&lt;br/&gt;Level: PT&lt;br/&gt;Version: 21.0&lt;br/&gt;SOC Term: 10029205 - Nervous system disorders&lt;br/&gt;Classification Code: 10080700&lt;br/&gt;Term: Relapsing multiple sclerosis&lt;br/&gt;Level: PT&lt;br/&gt;&lt;br/&gt;Population Age: Adults&lt;br/&gt;Gender: Male, Female&lt;br/&gt;Trial Protocol: &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/DE"&gt;DE&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/CZ"&gt;CZ&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/HU"&gt;HU&lt;/a&gt; (Ongoing), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/FI"&gt;FI&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/AT"&gt;AT&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/PL"&gt;PL&lt;/a&gt; (Completed), &lt;a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/IT"&gt;IT&lt;/a&gt; (Ongoing)&lt;/p&gt;</description><guid>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003995-42</guid></item>

As far as I can tell even in the single pages we don't have the information about which countries the trial is taking place.

image

This is what we get from the trial summary text file

EudraCT Number:          2020-003874-30
Sponsor Protocol Number: MS700568_0158
Sponsor Name:            Merck Healthcare KGaA
Full Title:              A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial
Start Date:              2021-02-03
Medical condition:       Highly-active relapsing multiple sclerosis
Disease:                 Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10029205, Term: Nervous system disorders, Level: SOC
Disease:                 Version: 20.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10028245, Term: Multiple sclerosis, Level: PT
Disease:                 Version: 21.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10080700, Term: Relapsing multiple sclerosis, Level: PT
Population Age:          Adults, Elderly
Gender:                  Male, Female
Trial protocol:          CZ(Completed) HU(Completed) SK(Ongoing) DK(Completed) AT(Completed) IT(Ongoing) 
Link:                    https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003874-30

Trial protocol seems to be a list of countries and the current status.

brunoamaral commented 12 months ago

the information we get from the WHO clinical trials database is well structured and includes a field for countries.

  <Trial><Export_date>10/25/2023 11:27:44</Export_date>
    <Internal_Number>13402386
    </Internal_Number>
    <TrialID>NCT06083194
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Evaluation of Muscle Oxidative Capacity Relationship With Muscular Endurance, Fatigue (Multiple Sclerosis).
    </Public_title>
    <Scientific_title>Non-invasive Evaluation of Muscle Oxidative Capacity. Study of Its Relationship With Muscular Endurance and Fatigue in Patients With Multiple Sclerosis
    </Scientific_title>
    <Acronym>OXYSEP
    </Acronym>
    <Primary_sponsor>University Hospital, Clermont-Ferrand
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231009
    </Date_registration3>
    <Date_registration>09/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06083194
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2023
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Fréderic COSTES;Lise LACLAUTRE;Lise LACLAUTRE
    </Contact_Lastname>
    <Contact_Email>;promo_interne_drci@chu-clermontferrand.fr;promo_interne_drci@chu-clermontferrand.fr
    </Contact_Email>
    <Contact_Tel>;334.73.754.963;334.73.754.963
    </Contact_Tel>
    <Contact_Affiliation>fcostes@chu-clermontferrand.fr;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with Multiple Sclerosis (MS) with a diagnosis established by MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a Kurtzke Expanded Disability Status Scale (EDSS) score &lt; 5.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body mass index (BMI) &lt; 30 Kg/m².&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Thickness of subcutaneous adipose tissue at the calf = 20 mm.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MS patients without neurological signs of flare-up since 1 month.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MS patients who have not had any treatment modification during the last 2 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects affiliated to French health care system (for France).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Volunteers who have given their written consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients suffering from progressive psychiatric pathologies (active psychosis, , etc.)&#x0D;&lt;br&gt;             or the presence of another serious unstabilized pathology (decompensated heart&#x0D;&lt;br&gt;             failure, progressive terminal cancer, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  People with poorly controlled or unstable cardiovascular disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major osteoarticular or neurological problems completely preventing the proper&#x0D;&lt;br&gt;             performance of the various tests.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persons under guardianship, curatorship, deprived of liberty or safeguarding justice.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or lactating women.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Multiple Sclerosis
    </Condition>
    <Primary_outcome>Maximal muscle oxidative capacity (mVO2);Muscular endurance of the gastrocnemius muscles
    </Primary_outcome>
    <Secondary_outcome>Ventilatory reserve (%);Demographics information;Medical information;Weight (Kg);Height (cm);Waist circumference (cm);Hip circumference (cm);Body Mass Index (Kg/m²);Body composition;Thickness of subcutaneous adipose tissue of the gastrocnemius muscles (mm);Functional capacity;Gastrocnemius muscle endurance (number of repetitions and time(sec));Physical activity level (;Fatigue (FACIT-F score);Vo2max (maximal oxygen consumption) (mL/Kg/min);Maximum power (Watts);Threshold power (Watts);Maximum heart rate (bpm);Threshold heart rate (bpm);Forced vital Capacity (L and % of the theoretical value);Forced Expiratory volume (L and % of the theoretical value);Tiffeneau ratio (%);Tissue saturation index (kNIRS, min-1)
    </Secondary_outcome>
    <Secondary_ID>RBHP 2023 COSTES
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>

  </Trial>
brunoamaral commented 11 months ago

completed on #357